High expression of Lgl2 and SLC7A5 correlates with poor survival in ER+ breast cancer patients treated with Tamoxifen, and depleting these proteins restored Tamoxifen sensitivity (Saito et al., 2019). Here, SLC7A5 is linked to breast cancer.